REGN Q4 2020 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$81B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2.4B+30.0% YoY

Gross Profit

$2.0B82.9% margin

Operating Income

$1.2B48.2% margin

Net Income

$1.1B47.4% margin

EPS (Diluted)

$10.24

QoQ Revenue Growth

+5.6%

Cash Flow

Operating Cash Flow

$1.2B

Free Cash Flow

$1.1B

Stock-Based Comp.

$122M

Balance Sheet

Total Assets

$17.2B

Total Liabilities

$6.1B

Stockholders' Equity

$11.0B

Cash & Equivalents

$2.2B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.4B	$1.9B	+30.0%
Gross Profit	$2.0B	$1.6B	+26.5%
Operating Income	$1.2B	$676M	+72.7%
Net Income	$1.1B	$792M	+45.1%

Revenue Segments

Product

$1.6B100%